These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27412009)

  • 21. The sixth international RASopathies symposium: Precision medicine-From promise to practice.
    Gripp KW; Schill L; Schoyer L; Stronach B; Bennett AM; Blaser S; Brown A; Burdine R; Burkitt-Wright E; Castel P; Darilek S; Dias A; Dyer T; Ellis M; Erickson G; Gelb BD; Green T; Gross A; Ho A; Holder JL; Inoue SI; Jelin AC; Kennedy A; Klein R; Kontaridis MI; Magoulas P; McConnell DB; McCormick F; Neel BG; Prada CE; Rauen KA; Roberts A; Rodriguez-Viciana P; Rosen N; Rumbaugh G; Sablina A; Solman M; Tartaglia M; Thomas A; Timmer WC; Venkatachalam K; Walsh KS; Wolters PL; Yi JS; Zenker M; Ratner N
    Am J Med Genet A; 2020 Mar; 182(3):597-606. PubMed ID: 31825160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell type-specific roles of RAS-MAPK signaling in learning and memory: Implications in neurodevelopmental disorders.
    Ryu HH; Lee YS
    Neurobiol Learn Mem; 2016 Nov; 135():13-21. PubMed ID: 27296701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RAS signalling in energy metabolism and rare human diseases.
    Dard L; Bellance N; Lacombe D; Rossignol R
    Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling RASopathies with Genetically Modified Mouse Models.
    Hernández-Porras I; Guerra C
    Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Update on the treatment of RASopathies].
    Duat-Rodriguez A; Hernandez-Martin A
    Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining RASopathy.
    Rauen KA
    Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35103797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myocardial KRAS(G12D) expression does not cause cardiomyopathy in mice.
    Dalin MG; Zou Z; Scharin-Täng M; Safari R; Karlsson C; Bergo MO
    Cardiovasc Res; 2014 Feb; 101(2):229-35. PubMed ID: 24259500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prenatal diagnosis of Rasopathies in Ras/MAPK signaling pathway].
    Zhang J; Zeng Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Nov; 37(11):1291-1295. PubMed ID: 33179243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders.
    Aoki Y; Niihori T; Narumi Y; Kure S; Matsubara Y
    Hum Mutat; 2008 Aug; 29(8):992-1006. PubMed ID: 18470943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RASopathies: unraveling mechanisms with animal models.
    Jindal GA; Goyal Y; Burdine RD; Rauen KA; Shvartsman SY
    Dis Model Mech; 2015 Aug; 8(8):769-82. PubMed ID: 26203125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity.
    Malaquias AC; Jorge AAL
    Mol Cell Endocrinol; 2021 Jan; 519():111040. PubMed ID: 33011209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo severity ranking of Ras pathway mutations associated with developmental disorders.
    Jindal GA; Goyal Y; Yamaya K; Futran AS; Kountouridis I; Balgobin CA; Schüpbach T; Burdine RD; Shvartsman SY
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):510-515. PubMed ID: 28049852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Capillary malformation-arteriovenous malformation syndrome].
    Galán-Gutiérrez M; Ruiz-Villaverde R
    An Pediatr (Barc); 2013 Dec; 79(6):374-6. PubMed ID: 23608018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skeletal muscle pathology in Costello and cardio-facio-cutaneous syndromes: developmental consequences of germline Ras/MAPK activation on myogenesis.
    Tidyman WE; Lee HS; Rauen KA
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):104-14. PubMed ID: 21495178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mosaic RASopathies: A review of disorders caused by somatic pathogenic variants in the genes of the RAS/MAPK pathway.
    Carli D; Resta N; Ferrero GB; Ruggieri M; Mussa A
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):520-529. PubMed ID: 36461154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
    Delire B; Stärkel P
    Eur J Clin Invest; 2015 Jun; 45(6):609-23. PubMed ID: 25832714
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical manifestations of mutations in RAS and related intracellular signal transduction factors.
    Zenker M
    Curr Opin Pediatr; 2011 Aug; 23(4):443-51. PubMed ID: 21750428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The musculoskeletal phenotype of the RASopathies.
    Stevenson DA; Yang FC
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):90-103. PubMed ID: 21495174
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rasopathies: developmental disorders that predispose to cancer and skin manifestations].
    Hernández-Martín A; Torrelo A
    Actas Dermosifiliogr; 2011; 102(6):402-16. PubMed ID: 21536246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
    Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.